相似文献
1
Emerging techniques to treat corneal neovascularisation.
Eye (Lond). 2012 Jan;26(1):2-12. doi: 10.1038/eye.2011.246. Epub 2011 Oct 7.
2
Corneal neovascularization: an anti-VEGF therapy review.
Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007.
3
Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
Invest Ophthalmol Vis Sci. 2013 Sep 11;54(9):6133-42. doi: 10.1167/iovs.13-12460.
4
Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1659-65. doi: 10.1167/iovs.08-1997. Epub 2008 Nov 7.
5
[Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Arch Soc Esp Oftalmol. 2013 Dec;88(12):473-81. doi: 10.1016/j.oftal.2013.07.007. Epub 2013 Oct 7.
6
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1375-82. doi: 10.1007/s00417-009-1099-1. Epub 2009 May 5.
7
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).
Br J Ophthalmol. 2007 Jun;91(6):804-7. doi: 10.1136/bjo.2006.107912. Epub 2006 Dec 19.
8
The effect of bevacizumab on corneal neovascularization in rabbits.
Korean J Ophthalmol. 2010 Aug;24(4):230-6. doi: 10.3341/kjo.2010.24.4.230. Epub 2010 Aug 3.
9
Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Cornea. 2014 Oct;33(10):1088-94. doi: 10.1097/ICO.0000000000000220.
10
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Cornea. 2008 Apr;27(3):349-52. doi: 10.1097/ICO.0b013e31815cf67d.
引用本文的文献
1
A cell-permeable peptide inhibitor of p55PIK signaling alleviates suture-induced corneal neovascularization and inflammation.
Heliyon. 2023 Mar 31;9(4):e14869. doi: 10.1016/j.heliyon.2023.e14869. eCollection 2023 Apr.
2
Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report.
Rom J Ophthalmol. 2021 Jul-Sep;65(3):286-289. doi: 10.22336/rjo.2021.58.
3
Knockdown of LncRNA SNHG1 Suppresses Corneal Angiogenesis by the Regulation of miR-195-5p/VEGF-A.
J Ophthalmol. 2021 Oct 19;2021:6646512. doi: 10.1155/2021/6646512. eCollection 2021.
4
Corneal angiogenic privilege and its failure.
Exp Eye Res. 2021 Mar;204:108457. doi: 10.1016/j.exer.2021.108457. Epub 2021 Jan 22.
5
Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization Via Inhibition of VEGF Production.
Pharmaceutics. 2020 Apr 28;12(5):404. doi: 10.3390/pharmaceutics12050404.
6
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.
Mol Med Rep. 2020 Jun;21(6):2571-2579. doi: 10.3892/mmr.2020.11056. Epub 2020 Apr 6.
7
lncRNA MIAT suppression alleviates corneal angiogenesis through regulating miR-1246/ACE.
Cell Cycle. 2019 Mar-Apr;18(6-7):661-669. doi: 10.1080/15384101.2019.1578143. Epub 2019 Mar 5.
8
Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization.
Int J Nanomedicine. 2016 Dec 30;12:279-294. doi: 10.2147/IJN.S114754. eCollection 2017.
9
Anti-apoptosis effects of vascular endothelial cadherin in experimental corneal neovascularization.
Int J Ophthalmol. 2015 Dec 18;8(6):1083-8. doi: 10.3980/j.issn.2222-3959.2015.06.01. eCollection 2015.
10
Role of Matrix Metalloproteinases in the Pathogenesis of Traumatic Brain Injury.
Mol Neurobiol. 2016 Nov;53(9):6106-6123. doi: 10.1007/s12035-015-9520-8. Epub 2015 Nov 5.
本文引用的文献
1
Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
Cornea. 2011 Oct;30(10):1071-7. doi: 10.1097/ICO.0b013e31820cd3f4.
2
Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable.
Br J Ophthalmol. 2012 Jan;96(1):3-9. doi: 10.1136/bjo.2011.204701. Epub 2011 Jun 28.
3
Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
Cornea. 2011 Oct;30(10):1110-4. doi: 10.1097/ICO.0b013e31821379aa.
4
Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.
Arch Ophthalmol. 2011 Apr;129(4):445-52. doi: 10.1001/archophthalmol.2011.42.
5
[Antiangiogenic therapy at the ocular surface: when, what and why?].
Ophthalmologe. 2011 Mar;108(3):230-6. doi: 10.1007/s00347-010-2262-0.
6
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.
7
Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis.
Ophthalmology. 2010 Jul;117(7):1300-5.e7. doi: 10.1016/j.ophtha.2010.01.039. Epub 2010 Jun 3.
8
Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Am J Ophthalmol. 2010 Oct;150(4):519-528.e1. doi: 10.1016/j.ajo.2010.04.024. Epub 2010 Jun 29.
9
Ocular angiogenesis: mechanisms and recent advances in therapy.
Adv Clin Chem. 2010;50:103-21.
10
The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6277-85. doi: 10.1167/iovs.09-4571. Epub 2010 Apr 30.
Zotero 插件